Bicara's CEO, Claire Mazumdar, expressed optimism about the company's momentum, particularly regarding the FORTIFI-HN01 pivotal trial for ficerafusp alfa, a bifunctional therapy targeting HPV-negative head and neck cancer. The company has selected a 1500mg weekly dose as optimal and has initiated Phase 3 of the trial, with interim analysis expected in mid-2027. Additionally, Bicara announced plans for a less frequent dosing schedule, which could enhance patient convenience and compliance.
The company also reported that research and development expenses rose to $33.0 million in Q4 2025, reflecting the costs associated with its clinical trials. General and administrative expenses increased to $8.1 million in the same quarter, driven by additional personnel costs and professional fees. Bicara's strategic focus on advancing its clinical programs and preparing for potential commercialization underscores its commitment to transforming outcomes for patients with significant unmet medical needs.
Looking ahead, Bicara anticipates key milestones, including presenting long-term follow-up data from its Phase 1b study at the upcoming ASCO Annual Meeting and achieving substantial enrollment in the FORTIFI-HN01 pivotal study by the end of 2026. The company is also preparing for critical commercial hires to advance its organizational readiness for a potential launch of ficerafusp alfa, pending regulatory approval.
